Pathogen Genomics and Genomic Surveillance Market (2026-2036)

The growth of this market is mainly driven by the institutionalization of genomic surveillance in public health systems after the COVID-19 pandemic, the continued emergence of infectious disease threats such as highly pathogenic avian influenza H5N1, mpox, and measles, the expansion of wastewater and environmental surveillance, and the growing use of whole-genome sequencing to track antimicrobial resistance and foodborne outbreaks. In addition, the adoption of metagenomic sequencing for clinical infectious disease diagnosis, the declining cost and increasing portability of sequencing, global initiatives to build surveillance capacity in low- and middle-income countries, and the use of artificial intelligence (AI) in genomic epidemiology are further supporting the growth of this market. However, the normalization of public health funding after the pandemic is moderating near-term growth.

The Pathogen Genomics and Genomic Surveillance Market, also referred to as the infectious disease genomics market, public health sequencing market, or microbial genomic surveillance market, comprises the instruments, consumables and reagents, software, and services used to sequence and analyze the genomes of viruses, bacteria, fungi, and parasites for disease surveillance, outbreak investigation, clinical diagnosis, antimicrobial resistance monitoring, food safety, and vaccine and drug development. The market includes short-read and long-read sequencers; whole-genome, targeted amplicon, and metagenomic library preparation kits and pathogen panels; bioinformatics and genomic epidemiology software; and sequencing and surveillance services, including wastewater and traveler-based surveillance programs and clinical metagenomic testing. The market ecosystem extends from sequencing platform and reagent providers to bioinformatics developers, public health laboratories, hospitals and clinical laboratories, academic and research institutes, food safety and animal health agencies, pharmaceutical and vaccine developers, and international organizations and funders.

The COVID-19 pandemic transformed pathogen genomics from a specialized research activity into a core public health capability. Countries around the world built sequencing capacity to track SARS-CoV-2 variants, and many have since expanded their programs to cover influenza, RSV, mpox, measles, foodborne pathogens, and antimicrobial-resistant bacteria. Genomic data allow public health agencies to identify new variants, trace transmission chains, detect outbreaks earlier, and evaluate vaccines and treatments. As a result, genomic surveillance is now embedded in national public health strategies and international health security frameworks.

Public health programs in the U.S. illustrate the scale and evolution of genomic surveillance. The U.S. National Wastewater Surveillance System (NWSS) of the Centers for Disease Control and Prevention (CDC) included about 1,300 testing sites covering about 144 million people as of June 2026, monitoring SARS-CoV-2, seasonal and avian influenza, RSV, measles, and mpox; the Consolidated Appropriations Act, 2026, signed in February 2026, averted an immediate funding crisis, but sustained funding beyond fall 2026 remains under discussion, with the American Society for Microbiology requesting at least USD 120 million for NWSS in the fiscal year 2027 budget. The CDC Traveler-based Genomic Surveillance program, launched in 2021, operates at nine U.S. international airports, analyzing voluntary nasal swabs from international travelers and wastewater from aircraft and airport facilities for more than 30 viral and bacterial targets. The CDC Advanced Molecular Detection (AMD) program supports the integration of genomics into public health laboratories, and genomic sequencing played a central role in the response to highly pathogenic avian influenza H5N1 in dairy cattle, where sequencing of virus from cattle, milk, and retail dairy products was used to track spillover events and viral evolution.

International initiatives are building capacity in regions with limited sequencing infrastructure. In April 2026, the International Pathogen Surveillance Network (IPSN), housed by the World Health Organization (WHO) Hub for Pandemic and Epidemic Intelligence in Berlin and funded by the Gates Foundation, Rockefeller Foundation, Wellcome Trust, and Institute of Philanthropy, launched a second round of USD 1.8 million in catalytic grants for pathogen genomic and wastewater and environmental surveillance in low- and middle-income countries. The Africa Pathogen Genomics Initiative, launched by the Africa Centres for Disease Control and Prevention (Africa CDC) with USD 100 million over four years from partners including the Gates Foundation, the U.S. CDC, Illumina, Oxford Nanopore Technologies, and Microsoft, has built genomic surveillance capacity in more than 20 African countries for COVID-19, HIV, tuberculosis, malaria, cholera, and other threats. These initiatives aim to ensure that new threats can be detected and characterized wherever they emerge and that genomic data are shared rapidly to support global response.

Clinical applications of pathogen genomics are expanding. Metagenomic next-generation sequencing can detect a broad range of pathogens in a single test without prior knowledge of the cause of infection, which is particularly valuable for immunocompromised patients and complex infections. In April 2026, Karius made its Karius Spectrum plasma test and Karius Focus BAL test, which use metagenomic next-generation sequencing (mNGS) to detect pathogens with results within 24 hours of sample receipt, available to order through Mayo Clinic Laboratories for immunocompromised patients with complicated infections. Whole-genome sequencing is also increasingly used in hospitals to investigate healthcare-associated infection outbreaks and characterize antimicrobial resistance, and targeted sequencing is used for tuberculosis drug resistance testing and HIV drug resistance analysis.

Technology developments are making pathogen sequencing faster, cheaper, and more accessible. Portable nanopore sequencers from Oxford Nanopore Technologies enable sequencing in field settings and resource-limited laboratories, while high-throughput short-read platforms from Illumina and others support large-scale surveillance. Pathogen panels and hybrid capture kits from companies such as Twist Bioscience, Illumina, and Thermo Fisher Scientific enable the detection of many pathogens in a single assay, and cloud-based bioinformatics platforms and open-source tools support the rapid analysis and sharing of genomic data.

At the same time, the market faces challenges related to the sustainability of public health funding after the pandemic, data sharing and integration, and workforce capacity. Ginkgo Bioworks, which partnered with the CDC on traveler-based surveillance, reported that its biosecurity revenue fell 30% to USD 37.4 million in 2025 and agreed to sell its biosecurity business to a group of investors, reflecting the decline of pandemic-era surveillance spending. As a result, providers that can deliver cost-effective, integrated surveillance solutions and demonstrate public health value beyond COVID-19 are expected to capture the largest share of growth over the forecast period.